|
1
|
Hirsch FR and Lippman SM: Advances in the
biology of lung cancer chemoprevention. J Clin Oncol. 23:3186–3197.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keith RL: Lung cancer chemoprevention.
Proc Am Thorac Soc. 9:52–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sandler AB and Dubinett SM: COX-2
inhibition and lung cancer. Semin Oncol. 31(Suppl 7): 45–52. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dy GK and Adjei AA: Novel targets for lung
cancer therapy: Part I. J Clin Oncol. 20:2881–2894. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen G, Kronenberger P, Teugels E, Umelo
IA and De Grève J: Targeting the epidermal growth factor receptor
in non-small cell lung cancer cells: The effect of combining RNA
interference with tyrosine kinase inhibitors or cetuximab. BMC Med.
10:282012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cuneo KC, Nyati MK, Ray D and Lawrence TS:
EGFR targeted therapies and radiation: Optimizing efficacy by
appropriate drug scheduling and patient selection. Pharmacol Ther.
154:67–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gasparini G, Longo R, Sarmiento R and
Morabito A: Inhibitors of cyclooxygenase 2: A new class of
anticancer agents? Lancet Oncol. 4:605–615. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Breyer MD, Harris RC and Matthew D:
Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens.
10:89–98. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frungieri MB, Calandra RS, Mayerhofer A
and Matzkin ME: Cyclooxygenase and prostaglandins in somatic cell
populations of the testis. Reproduction. 149:R169–R180. 2015.
View Article : Google Scholar
|
|
12
|
Vosooghi M and Amini M: The discovery and
development of cyclooxygenase-2 inhibitors as potential anticancer
therapies. Expert Opin Drug Discov. 9:255–267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghosh N, Chaki R, Mandal V and Mandal SC:
COX-2 as a target for cancer chemotherapy. Pharmacol Rep.
62:233–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rizzo MT: Cyclooxygenase-2 in oncogenesis.
Clin Chim Acta. 412:671–687. 2011. View Article : Google Scholar
|
|
15
|
Grösch S, Maier TJ, Schiffmann S and
Geisslinger G: Cyclooxygenase-2 (COX-2)-independent
anticarcinogenic effects of selective COX-2 inhibitors. J Natl
Cancer Inst. 98:736–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liggett JL, Zhang X, Eling TE and Baek SJ:
Anti-tumor activity of non-steroidal anti-inflammatory drugs:
Cyclooxygenase-independent targets. Cancer Lett. 346:217–224. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kismet K, Akay MT, Abbasoglu O and Ercan
A: Celecoxib: A potent cyclooxygenase-2 inhibitor in cancer
prevention. Cancer Detect Prev. 28:127–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu T, Leng J, Han C and Demetris AJ: The
cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt
and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer
Ther. 3:299–307. 2004.PubMed/NCBI
|
|
19
|
Jendrossek V: Targeting apoptosis pathways
by Celecoxib in cancer. Cancer Lett. 332:313–324. 2013. View Article : Google Scholar
|
|
20
|
Ramer R, Walther U, Borchert P, Laufer S,
Linnebacher M and Hinz B: Induction but not inhibition of COX-2
confers human lung cancer cell apoptosis by celecoxib. J Lipid Res.
54:3116–3129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frydrychowicz M, Kolecka-Bednarczyk A,
Madejczyk M, Yasar S and Dworacki G: Exosomes - structure,
biogenesis and biological role in non-small-cell lung cancer. Scand
J Immunol. 81:2–10. 2015. View Article : Google Scholar
|
|
22
|
Miller IV and Grunewald TG: Tumour-derived
exosomes: Tiny envelopes for big stories. Biol Cell. 107:287–305.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nazimek K, Bryniarski K, Santocki M and
Ptak W: Exosomes as mediators of intercellular communication:
Clinical implications. Pol Arch Med Wewn. 125:370–380.
2015.PubMed/NCBI
|
|
24
|
Zhang X, Yuan X, Shi H, Wu L, Qian H and
Xu W: Exosomes in cancer: Small particle, big player. J Hematol
Oncol. 8:832015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Milane L, Singh A, Mattheolabakis G,
Suresh M and Amiji MM: Exosome mediated communication within the
tumor microenvironment. J Control Release. 219:278–294. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hannafon BN and Ding WQ: Intercellular
communication by exosome-derived microRNAs in cancer. Int J Mol
Sci. 14:14240–14269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Li S, Li L, Li M, Guo C, Yao J
and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roma-Rodrigues C, Fernandes AR and
Baptista PV: Exosome in tumour microenvironment: Overview of the
crosstalk between normal and cancer cells. Biomed Res Int.
2014:1794862014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Höper MM, Voelkel NF, Bates TO, Allard JD,
Horan M, Shepherd D and Tuder RM: Prostaglandins induce vascular
endothelial growth factor in a human monocytic cell line and rat
lungs via cAMP. Am J Respir Cell Mol Biol. 17:748–756. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiang HG, Xie X, Hu FQ, Xiao HB, Zhang WJ
and Chen L: Cyclooxygenase-2 inhibition as a strategy for treating
gastric adenocarcinoma. Oncol Rep. 32:1140–1148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fatima N, Yi M, Ajaz S, Stephens RM,
Stauffer S, Greenwald P, Munroe DJ and Ali IU: Altered gene
expression profiles define pathways in colorectal cancer cell lines
affected by celecoxib. Cancer Epidemiol Biomarkers Prev.
17:3051–3061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dai ZJ, Ma XB, Kang HF, Gao J, Min WL,
Guan HT, Diao Y, Lu WF and Wang XJ: Antitumor activity of the
selective cyclo-oxygenase-2 inhibitor, celecoxib, on breast cancer
in vitro and in vivo. Cancer Cell Int. 12:532012. View Article : Google Scholar
|
